作者
John R Bergquist, Carlos A Puig, Christopher R Shubert, Ryan T Groeschl, Elizabeth B Habermann, Michael L Kendrick, David M Nagorney, Rory L Smoot, Michael B Farnell, Mark J Truty
发表日期
2016/7/1
期刊
Journal of the American College of Surgeons
卷号
223
期号
1
页码范围
52-65
出版商
No longer published by Elsevier
简介
Background
Patient triage in anatomically resectable, early stage pancreatic ductal adenocarcinoma (PDAC) with elevated carbohydrate antigen 19-9 (CA 19-9) remains unclear. We hypothesized that any CA 19-9 elevation indicates biologically borderline resectability.
Study Design
The National Cancer Data Base (NCDB 2010 to 2012) was reviewed for PDAC patients with reported CA 19-9. Nonsecretors were analyzed separately. Early stage (I/II) patients were stratified by CA 19-9 above or below normal (37 U/mL). Unadjusted Kaplan-Meier and adjusted Cox proportional hazards survival modeling were performed.
Results
Of 113,145 patients, only 28,074 (24.8%) had CA 19-9 measured and reported, and this proportion was stage independent. Among early stage patients (n = 10,806), there were 957 (8.8%) nonsecretors, 2,708 (25.1%) with normal levels, and 7,141 (66.1%) with elevated levels. Demographics …
学术搜索中的文章
JR Bergquist, CA Puig, CR Shubert, RT Groeschl… - Journal of the American College of Surgeons, 2016